Holen Sie sich die Stockscreener-App
0.20
3.11%
0.01
Schlusskurs vom Vortag:
$0.19
Offen:
$0.1708
24-Stunden-Volumen:
72.05M
Relative Volume:
1.93
Marktkapitalisierung:
$36.52M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-121.02M
KGV:
-0.0107
EPS:
-18.6875
Netto-Cashflow:
$-114.09M
1W Leistung:
+39.93%
1M Leistung:
+3.16%
6M Leistung:
-96.67%
1J Leistung:
-98.75%
1-Tages-Spanne:
$0.1685
$0.212
1-Wochen-Bereich:
$0.1264
$0.2763
52-Wochen-Spanne:
$0.118
$22.14
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
26 MAIN STREET, SUITE 101, CHATHAM, NY
Vergleichen Sie TNXP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| TNXP | 0.1997 | 36.52M | 0 | -121.02M | -114.09M | -18.69 |
| VRTX | 450.01 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.02 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 594.70 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.85 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.66 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals Holding (STU:TPM0) EV-to-Revenue : 0.99 (As of Nov. 20, 2024) - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Enterprise Value : $10.87 Mil (As of Nov. 20, 2024) - GuruFocus.com
Can Tonix Pharma's TNX-102 SL End The 15-Year Drug Drought In Fibromyalgia? - RTTNews
TNXPTonix Pharmaceuticals Holding Corp. Latest Stock News & Market Updates - StockTitan
Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual - The Manila Times
Tonix Pharmaceuticals to Present Pipeline Updates at Winter 2024 Investor Summit | TNXP Stock News - StockTitan
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting - The Manila Times
Tonix Pharmaceuticals Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology Convergence 2024 Annual Meeting - Marketscreener.com
TNXP (Tonix Pharmaceuticals Holding) Interest Coverage : N/A (As of Jun. 2024) - GuruFocus.com
Armistice Capital, LLC Acquires New Stake in Tonix Pharmaceutica - GuruFocus.com
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments - AccessWire
KEMRI partners with US firm Tonix Pharmaceuticals to develop mpox vaccine - The Eastleigh Voice News
Tonix reports less virulent mpox vaccine candidate - Investing.com India
Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting - The Manila Times
Tonix Pharma to Present Key Fibromyalgia Drug Data, Awaits FDA Decision on Fast-Tracked Treatment | TNXP Stock News - StockTitan
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals - The Manila Times
Tonix's TNX-801 Vaccine Shows Breakthrough Safety Results, 1000x More Effective Than Legacy Vaccines | TNXP Stock News - StockTitan
Tonix Pharma earnings beat by $2.70, revenue fell short of estimates - Investing.com
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tonix Pharmaceuticals Files FDA Application for First New Fibromyalgia Drug in 15 Years | TNXP Stock News - StockTitan
Tonix Pharma Unveils Promising TNX-1700 Cancer Data - TipRanks
Tonix presents new data on TNX-801 mpox vaccine - BioWorld Online
Tonix Pharma Partners for Vaccine Clinical Trial - Yahoo Finance
Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya - The Manila Times
Tonix Pharmaceuticals Holding Corp. Announces Research Agreement with Kenya Medical Research Institute to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya - Marketscreener.com
Tonix Pharmaceuticals (TNXP) Earnings Date and Reports 2024 - MarketBeat
Tonix reports promising mpox vaccine candidate data By Investing.com - Investing.com South Africa
Tonix reports promising mpox vaccine candidate data - Investing.com
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 - The Manila Times
Tonix Pharmaceuticals CEO Discusses New Drug Application for Fibromyalgia Treatment - Proactive Investors UK
Tonix Pharmaceuticals Holding (LTS:0A4T) PE Ratio (TTM) : At Loss (As of Oct. 29, 2024) - GuruFocus.com
Tonix Pharmaceuticals to Present at BIO-Europe® 2024 - StockTitan
Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference - StockTitan
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024 - Yahoo Finance
Tonix Pharmaceuticals Holding (FRA:TPM0) Purchase Of Proper - GuruFocus.com
Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency - Marketscreener.com
Tonix Pharma gets DoD contract for antiviral development - Investing.com
Tonix Pharma Secures Defense Contract for Antiviral Development - TipRanks
Tonix Pharma gets DoD contract for antiviral development By Investing.com - Investing.com UK
Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA) - The Manila Times
Tonix Pharma reports outcomes from CMC guidance meeting with FDA on Tonmya - Reuters.com
Empery Asset Management LP Acquires Shares in Tonix Pharmaceuticals - Yahoo Finance
Tonix Pharmaceuticals files NDA for fibromyalgia drug - Investing.com
Tonix Pharmaceuticals files NDA for fibromyalgia drug By Investing.com - Investing.com UK
Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) - Yahoo Finance
Tonix Pharmaceuticals Partners with X-Chem for AI-Driven Antiviral Development - MSN
Tonix and X-Chem collaborate to accelerate broad-spectrum antiviral development - BioWorld Online
Tonix Pharma Enhances Drug Development with AI Partnership - Yahoo Finance
Tonix secures DoD contract for antiviral drug development By Investing.com - Investing.com South Africa
Tonix secures DoD contract for antiviral drug development - Investing.com
Why Tonix Pharmaceuticals (TNXP) Stock Is Moving - Benzinga
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):